Epitope-based Therapeutic Targets in HCV Genotype 1 Non-structural Proteins: a Novel Strategy to Combat Emerging Drug Resistance

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Nov 22

PMID 39575309

Authors

Mireayi Tudi

Adili Sawuti

Maimaitituerhong Abudurusuli

Chao Wu

Xiaoyu Chen

Gulimire Ailimu

Kuerbannisa Wulayin

Maimaitiaili Tuerxun

Affiliations

Soon will be listed here.

Abstract

Introduction: The hepatitis C virus (HCV) poses a major global health challenge, with its non-structural proteins being essential for viral replication and pathogenesis. Mutations in these proteins significantly contribute to drug resistance, necessitating innovative therapeutic strategies. This study aims to identify epitope-based therapeutic targets in the non-structural proteins of HCV genotype 1, employing in-depth in silico tools to counteract emerging drug resistance.

Methods: We retrieved approximately 250 sequences of each non-structural protein from the NCBI database, capturing a broad spectrum of variability and sequence alignments, variability analysis and physicochemical property analysis were conducted. We utilized the TEPITOOL server by IEDB to predict cytotoxic T lymphocyte (CTL) epitopes. Following this, we assessed the efficiency of TAP transport and proteasomal cleavage using IEDB's combined predictor tool. The epitopes were selected based on conservancy analysis, immunogenicity, allergenicity, and presence in non-glycosylated regions, ensuring high predictive scores and suitability as vaccine candidates. Epitopes were docked with the HLA-A*02:01 allele and Toll-like receptor-3 using the ClusPro server. The immune response potential of the epitopes was evaluated through immune stimulation.

Results: The study identified 27 potential CTL epitopes from the non-structural proteins, including NS3, NS4a, NS4b, NS5a, and NS5b. Out of these, three lead epitopes demonstrated high conservation (>90%), strong binding affinities to HLA-A*02:01 and TLR-3, and robust immune response potential. These epitopes also showed favorable characteristics such as being non-allergenic and non-glycosylated.

Conclusion: This comprehensive analysis provides a promising foundation for developing an epitope-based vaccine targeting HCV non-structural proteins, offering a novel approach to overcoming drug resistance in HCV treatment.

References

Oli A, Obialor W, Ifeanyichukwu M, Odimegwu D, Okoyeh J, Emechebe G . Immunoinformatics and Vaccine Development: An Overview. Immunotargets Ther. 2020; 9:13-30. PMC: 7049754. DOI: 10.2147/ITT.S241064. View

Paul S, Sidney J, Sette A, Peters B . TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates. Curr Protoc Immunol. 2016; 114:18.19.1-18.19.24. PMC: 4981331. DOI: 10.1002/cpim.12. View

Rizarullah , Aditama R, Giri-Rachman E, Hertadi R . Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches. ACS Omega. 2024; 9(14):16547-16562. PMC: 11007845. DOI: 10.1021/acsomega.4c00425. View

Gupta R, Brunak S . Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput. 2002; :310-22. View

Cowton V, Owsianka A, Fadda V, Ortega-Prieto A, Cole S, Potter J . Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines. 2021; 6(1):7. PMC: 7794244. DOI: 10.1038/s41541-020-00269-1. View

Shen C, Jiang X, Li M, Luo Y . Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel). 2023; 15(2). PMC: 9856776. DOI: 10.3390/cancers15020533. View

Dobrowolska K, Brzdek M, Rzymski P, Flisiak R, Pawlowska M, Janczura J . Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert Opin Pharmacother. 2024; 25(7):833-852. DOI: 10.1080/14656566.2024.2358139. View

Dimitrov I, Bangov I, Flower D, Doytchinova I . AllerTOP v.2--a server for in silico prediction of allergens. J Mol Model. 2014; 20(6):2278. DOI: 10.1007/s00894-014-2278-5. View

Kozakov D, Hall D, Xia B, Porter K, Padhorny D, Yueh C . The ClusPro web server for protein-protein docking. Nat Protoc. 2017; 12(2):255-278. PMC: 5540229. DOI: 10.1038/nprot.2016.169. View

10.

Shawan M, Sharma A, Halder S, Arian T, Shuvo M, Sarker S . Advances in Computational and Bioinformatics Tools and Databases for Designing and Developing a Multi-Epitope-Based Peptide Vaccine. Int J Pept Res Ther. 2023; 29(4):60. PMC: 10203685. DOI: 10.1007/s10989-023-10535-0. View

11.

Bui H, Sidney J, Li W, Fusseder N, Sette A . Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics. 2007; 8:361. PMC: 2233646. DOI: 10.1186/1471-2105-8-361. View

12.

Chauhan V, Singh M, Ratho R . Identification of T cell and B cell epitopes against Indian HCV-genotype-3a for vaccine development- An in silico analysis. Biologicals. 2018; 53:63-71. DOI: 10.1016/j.biologicals.2018.02.003. View

13.

Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz M . Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 2005; 62(9):1025-37. DOI: 10.1007/s00018-005-4528-2. View

14.

Izhari M . Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections. Diagnostics (Basel). 2023; 13(19). PMC: 10572573. DOI: 10.3390/diagnostics13193102. View

15.

Doytchinova I, Flower D . VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8:4. PMC: 1780059. DOI: 10.1186/1471-2105-8-4. View

16.

Chauhan V, Singh M . Immuno-informatics approach to design a multi-epitope vaccine to combat cytomegalovirus infection. Eur J Pharm Sci. 2020; 147:105279. DOI: 10.1016/j.ejps.2020.105279. View

17.

Ramos D, Pinto M, Sousa Coutinho R, Silva C, Quina M, Gomes J . Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus. Pathogens. 2023; 12(6). PMC: 10302339. DOI: 10.3390/pathogens12060754. View

18.

Muteeb G, Rehman M, Pani B, Khan R . Editorial: Novel drug-designing approaches to combat antimicrobial resistance. Front Mol Biosci. 2024; 10:1342702. PMC: 10808710. DOI: 10.3389/fmolb.2023.1342702. View

19.

Chauhan V, Rungta T, Rawat M, Goyal K, Gupta Y, Singh M . Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach. J Cell Physiol. 2020; 236(2):1131-1147. PMC: 7361924. DOI: 10.1002/jcp.29923. View

20.

Papadopoulos J, Agarwala R . COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007; 23(9):1073-9. DOI: 10.1093/bioinformatics/btm076. View